227 related articles for article (PubMed ID: 7935635)
1. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.
Virgolini I; Raderer M; Kurtaran A; Angelberger P; Banyai S; Yang Q; Li S; Banyai M; Pidlich J; Niederle B; Scheithauer W; Valent P
N Engl J Med; 1994 Oct; 331(17):1116-21. PubMed ID: 7935635
[TBL] [Abstract][Full Text] [Related]
2. 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract.
Virgolini I; Raderer M; Kurtaran A; Angelberger P; Yang Q; Radosavljevic M; Leimer M; Kaserer K; Li SR; Kornek G; Hübsch P; Niederle B; Pidlich J; Scheithauer W; Valent P
Nucl Med Biol; 1996 Aug; 23(6):685-92. PubMed ID: 8940711
[TBL] [Abstract][Full Text] [Related]
3. Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy.
Raderer M; Becherer A; Kurtaran A; Angelberger P; Li S; Leimer M; Weinlaender G; Kornek G; Kletter K; Scheithauer W; Virgolini I
J Nucl Med; 1996 Sep; 37(9):1480-7. PubMed ID: 8790198
[TBL] [Abstract][Full Text] [Related]
4. Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer.
Raderer M; Kurtaran A; Yang Q; Meghdadi S; Vorbeck F; Hejna M; Angelberger P; Kornek G; Pidlich J; Scheithauer W; Virgolini I
J Nucl Med; 1998 Sep; 39(9):1570-5. PubMed ID: 9744345
[TBL] [Abstract][Full Text] [Related]
5. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging.
Reubi JC
J Nucl Med; 1995 Oct; 36(10):1846-53. PubMed ID: 7562054
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours.
Hessenius C; Bäder M; Meinhold H; Böhmig M; Faiss S; Reubi JC; Wiedenmann B
Eur J Nucl Med; 2000 Nov; 27(11):1684-93. PubMed ID: 11105825
[TBL] [Abstract][Full Text] [Related]
7. Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy.
Virgolini I; Kurtaran A; Leimer M; Kaserer K; Peck-Radosavljevic M; Angelberger P; Hübsch P; Dvorak M; Valent P; Niederle B
J Nucl Med; 1998 Sep; 39(9):1575-9. PubMed ID: 9744346
[TBL] [Abstract][Full Text] [Related]
8. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
9. The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors.
Kisker O; Bartsch D; Weinel RJ; Joseph K; Welcke UH; Zaraca F; Rothmund M
J Am Coll Surg; 1997 May; 184(5):487-92. PubMed ID: 9145069
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification.
Reubi JC; Waser B; Laissue JA; Gebbers JO
Cancer Res; 1996 Apr; 56(8):1922-31. PubMed ID: 8620515
[TBL] [Abstract][Full Text] [Related]
11. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor imaging of endocrine gastrointestinal tumors.
Krenning EP; Kwekkeboom DJ; Oei HY; Reubi JC; van Hagen PM; Kooij PP; Reijs AE; Lamberts SW
Schweiz Med Wochenschr; 1992 Apr; 122(17):634-7. PubMed ID: 1350377
[TBL] [Abstract][Full Text] [Related]
13. [Somatostatin receptor scintigraphy in preoperative diagnosis of the site of endocrine gastrointestinal tumors].
Weinel RJ; Kisker O; Joseph K; Welcke U; Zaraca F; Rothmund M
Chirurg; 1994 Oct; 65(10):849-55. PubMed ID: 7821043
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide and somatostatin receptor scintigraphy for differential diagnosis of hepatic carcinoid metastasis.
Kurtaran A; Raderer M; Müller C; Prokesch R; Kaserer K; Eibenberger K; Koperna K; Niederle B; Virgolini I
J Nucl Med; 1997 Jun; 38(6):880-1. PubMed ID: 9189133
[TBL] [Abstract][Full Text] [Related]
15. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide receptor scintigraphy.
Virgolini I; Kurtaran A; Raderer M; Leimer M; Angelberger P; Havlik E; Li S; Scheithauer W; Niederle B; Valent P
J Nucl Med; 1995 Oct; 36(10):1732-9. PubMed ID: 7562036
[TBL] [Abstract][Full Text] [Related]
17. Imaging tumors with peptide-based radioligands.
Behr TM; Gotthardt M; Barth A; Béhé M
Q J Nucl Med; 2001 Jun; 45(2):189-200. PubMed ID: 11476170
[TBL] [Abstract][Full Text] [Related]
18. 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.
Raderer M; Kurtaran A; Hejna M; Vorbeck F; Angelberger P; Scheithauer W; Virgolini I
Br J Cancer; 1998 Jul; 78(1):1-5. PubMed ID: 9662242
[TBL] [Abstract][Full Text] [Related]
19. Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998.
Raderer M; Kurtaran A; Leimer M; Angelberger P; Niederle B; Vierhapper H; Vorbeck F; Hejna MH; Scheithauer W; Pidlich J; Virgolini I
J Clin Oncol; 2000 Mar; 18(6):1331-6. PubMed ID: 10715305
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors.
Krausz Y; Bar-Ziv J; de Jong RB; Ish-Shalom S; Chisin R; Shibley N; Glaser B
Am J Gastroenterol; 1998 Jan; 93(1):66-70. PubMed ID: 9448177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]